Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2587-2597

  Fizazi, Karim ^a   Yang, Jun ^a   Peleg, Sara ^a   Sikes, Charles R ^a   Kreimann, Erica L ^a   Daliani, Danai ^a   Olive, Matilde ^a   Raymond, Kevin A ^a   Janus, Todd J ^c   Logothetis, Christopher J ^a   Karsenty, Gerard ^b   Navone, Nora M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGENIC AGENT; OSTEOPROTEGERIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; ATTENUATION; BONE MASS; BONE METASTASIS; CARCINOGENESIS; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; COCULTURE; CONTROLLED STUDY; DOUBLE MINUTE CHROMOSOME; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SCID MOUSE;

ALKALINE PHOSPHATASE; ANIMALS; BLOTTING, NORTHERN; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DNA; DNA, COMPLEMENTARY; DOWN-REGULATION; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOPROTEGERIN; PHENOTYPE; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA; RNA, MESSENGER;

EID: 12444308202     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics. CA - Cancer J. Clin., 51: 15-36, 2001.
2. Koutsilieris, M., Laroche, B., Thabet, M., and Fradet, Y. The assessment of disease aggressivity in stage D2 prostate cancer patients. Anticancer Res., 10: 333-336, 2001.
3. Cook, G. B., and Watson, F. R. Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J. Urol., 96: 87-96, 1968.
4. Orr, F. W., and Singh, G. Bone metastasis: mechanisms and pathophysiology. Austin: R. G. Landes, 1996.
5. Navone, N. M., Logothetis, C. J., von Eschenbach, A. C., and Troncoso, P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev., 17: 361-371, 1999.
6. Pretlow, T. G., and Pretlow, T. Models of prostate cancer. In: M. I. Resnick and I. M. Thompson (eds.), Advanced Therapy of Prostate Disease, pp. 138-153. London: B. C. Decker, Inc., 2000.
7. Koeneman, K. S., Yeung, F., and Chung, L. W. K. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39: 246-261, 1999.
8. Boyce, B. F., Yoneda, T., and Guise, T. A. Factors regulating the growth of metastatic cancer in bone. Endocr. Relat. Cancer, 6: 333-347, 1999.
9. Pirtskhalaishvili, G., and Nelson, J. B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate, 44: 77-87, 2000.
10. Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., and Simons, J. W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med., 1: 944-949, 1995.
11. Kopetz, E. S., Nelson, J. B., and Carducci, M. A. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Investig. New Drugs, 20: 173-182, 2002.
12. Kasperk, C. H., Borcsok, I., Schairer, H. U., Schneider, U., Nawroth, P. P., Niethard, F. U., and Ziegler, R. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif. Tissue Int., 60: 368-374, 1997.
13. Pietrzkowski, Z., Mulholland, G., Gomella, L., Jameson, B. A., Wemicke, D., and Baserga, R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res., 53: 1102-1106, 1993.
14. Ritchie, C. K., Andrews, L. R., Thomas, K. G., Tindall, D. J., and Fitzpatrick, L. A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology, 138: 1145-1150, 1997.
15. Conover, C. The role of insulin-like growth factors and binding proteins in bone cell biology. In: J. P. Bilezikian, L. G. Raisz, and G. A. Rodan (eds.), Principles of Bone Biology, pp. 607-618. New York: Academic Press, 1996.
16. Yu, H., and Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. (Bethesda), 92: 1472-1489, 2000.
17. Clarke, N. W., McClure, J., and George, N. J. R. Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol., 68: 74-80, 1991.
18. Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Coleman, R. E., and Delmas, P. D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer, 82: 858-864, 2000.
19. Dearnaley, P. Preliminary evidence that oral Clodronate delays symptomatic progression of bone metastasis from prostate cancer: first results of the MRC Pr05 trial. Presentations in Focus. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 174a, 2001.
20. Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T., and Mundy, G. R. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Investig., 98: 1544-1549, 1996.
21. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M-S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H-L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W. J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89: 309-319, 1997.
22. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., and Simonet, W. S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev., 12: 1260-1268, 1998.
23. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y-X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176, 1998.
24. Honore, P., Luger, N. M., Sabino, M. A., Schwei, M. J., Rogers, S. D., Mach, D. B., O'Keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., and Mantyh, P. W. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med., 6: 521-528, 2000.
25. Partridge, N. C., and Winchester, S. K. Osteoblast proteinases. In: J. P. Bilezikian, L. G. Raisz, and G. A. Rodan (eds.), Principles of Bone Biology. New York: Academic Press, pp. 207-616, 1996.
26. Navone, N. M., Olive, M., Ozen, M., Davis, R., Troncoso, P., Tu, S. M., Johnston, D., Pollack, A., Pathak, S., von Eschenbach, A. C., and Logothetis, C. J. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res., 3: 2493-2500, 1997.
27. Navone, N. M., Rodriguez-Vargas, M. D. C., Benedict, W. F., Troncoso, P., McDonnell, T. J., Zhou, J. H., Luthra, R., and Logothetis, C. J. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin. Cancer Res., 6: 1190-1197, 2000.
28. Yang, J., Fizazi, K., Peleg, S., Sikes, C. R., Raymond, A. K., Jamal, N., Hu, M., Olive, M., Martinez, L. A., Wood, C. G., Logothetis, C. J., Karsenty, G., Nora, M., and Navone, N. M. Prostate cancer cells induce osteoblast differentiation through a cbfa1-dependent pathway. Cancer Res., 61: 5652-5659, 2001.
29. Freshney, R. I. Culture of animal cells. A manual of basic techniques, Ed. 2. New York: Wiley-Liss, Inc., 1994.
30. Laborda, J. 36B4 cDNA used as an estradiol-independent MRNA control is the CDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res., 19: 3998, 1991.
31. Doherty, A., Smith, G., Banks, L., Christmas, T., and Epstein, R. J. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth. J. Pathol., 188: 278-281, 1999.
32. Smith, G. L., Doherty, A. P., Mitchell, H., Hanham, I. W., Christmas, T. J., and Epstein, R. J. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer. Lancet, 354: 2053-2054, 1999.
33. Shariat, S. F., Lamb, D. J., Kattan, M. W., Nguyen, C., Kim, J. H., Beck, J., Wheeler, T. M., and Slawin, K. M. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J. Clin. Oncol., 20: 833-884, 2002.
34. Chan, J. M., Stampfer, M. J., Gann, P., Gazizno, M., Pollak, M., and Giovannucci, E. Insulin-like growth factor-I (IGF-I) and IGF binding protein -3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. (Bethesda), 94: 1099-1106, 2002.
35. Kanety, H., Madjar, Y., Dagan, Y., Levi, J., Papa, M. Z., Pariente, C., Goldwasser, B., and Karasik, A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab., 77: 229-233, 1993.
36. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, L. P., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. (Bethesda), 85: 1657-1669, 1993.
37. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C. J., Chung, L. W., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the proto-oncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6945, 1992.
38. Geldof, A. A., and Rao, B. R. Prostatic tumor (R3327) skeletal metastasis. Prostate, 16: 279-290, 1990.
39. Soos, G., Jones, R. F., Haas, G. P., and Wang, C. Y. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC3 in the nude mouse. Anticancer Res., 17: 4253-4258, 1997.
40. Opgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B., Gehrke, L. J., Hernandez, L., Magnuson, S. R., Marsh, K. C., Novosad, E. I., Von Geldern, T. W., Wessale, J. L., Winn, M., and Wu-Wong, J. R. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther., 276: 473-481, 1996.
41. Zonnenberg, B. A., Anbaum, B., Kronemeier, R., Yang, F., Samra, E., Janus, T. J., Padley, R. I., Grahn, A., and Groenewegen, G. Results of an initial Phase I dose-escalation study of endothelin-1 receptor antagonist ABT-627 in patients with hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 163a, 1999.
42. Carducci, M. A., Vogelzang, N. J., Daliani, D., Dawson, M., Hippensteel, R., Padley, R. J., and Janus T. J. A placebo (PBO) controlled Phase II dose-ranging evaluation of an endothelin-A receptor antagonist for men with hormone-refractory prostate cancer (HRPCa) and disease-related pain. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 334a, 2000.
43. Nelson, J. B., Carducci, M. A., Padley, R. J., Janus, T. J., Humerickhouse, R., and Hippensteel, R. The endothelin-A receptor antagonist Atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 12, 2001.
44. Zhao, G., Monier-Faugere, M-C., Langub, M. C., Geng, Z., Nakayama, T., Pike, J. W., Chernausek, S. D., Rosen, C. J., Donahue, L-H., Malluche, H. H., Fagin, J. A., and Clemens, T. L. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology, 141: 2674-2682, 2000.
45. Daujat, S., Neel, H., and Piette, J. MDM2: life without p53. Trends Genet., 17: 459-464, 2001.
46. Clohisy, D. R., Ramnaraine, M. L., Scully, S., Qi, M., Van, G., Tan, H. L., and Lacey, D. L. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J. Orthop. Res., 18: 967-976; 2000.
47. Zhang, J., Dai, J., Qi, Y., Lin, D. L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., and Keller, E. T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Investig., 107: 1235-1244, 2001.
48. Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., and Vessella, R. L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 57: 611-616, 2001.
49. Kuss, B., and Cotter, F. Antisense: time to shoot the messenger. Ann. Oncol., 10: 495-503, 1999.
50. Capoulade, C., Mir, L. M., Carlier, K., Lecluse, Y., Tetaud, C., Mishal, Z., and Wiels, J. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood, 97: 1043-1049, 2001.
51. Maulard, C., Richaud, P., Droz, J. P., Jessueld, D., Dufour-Esquerre, F., and Housset, M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol., 36: 259-262, 1995.
52. Koutsilieris, M., Tzanela, M., and Dimopoulos, T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate, 38: 313-316, 1999.